订阅服务 - Biotech Analysis Central提供制药公司的深度分析服务 每月订阅费49美元 年度订阅可享受3350%折扣 年费399美元 [1] - 服务内容包括600多篇生物科技投资文章 10多只中小盘股票的投资组合模型 实时聊天以及各类分析和新闻报告 [2] 公司研究 - 文章提及Tiziana Life Sciences (NASDAQ: TLSA)及其药物Foralumab的研发进展 [2]

Foralumab is the only fully human anti-CD3 monoclonal antibody (mAb) currently in clinical development. The non-active SPMS intranasal foralumab Phase 2 trial (NCT06292923) began screening patients in November of 2023. Immunomodulation by intranasal foralumab represents a novel avenue for treatment of neuroinflammatory and neurodegenerative human diseases. NEW YORK, May 12, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences Ltd. (Nasdaq: TLSA) ("Tiziana" or the "Company"), a biotechnology company developing bre ...